vs

Side-by-side financial comparison of Insight Molecular Diagnostics Inc. (IMDX) and Beyond Air, Inc. (XAIR). Click either name above to swap in a different company.

Beyond Air, Inc. is the larger business by last-quarter revenue ($2.2M vs $1.1M, roughly 1.9× Insight Molecular Diagnostics Inc.). Beyond Air, Inc. runs the higher net margin — -334.4% vs -2015.4%, a 1681.0% gap on every dollar of revenue. On growth, Beyond Air, Inc. posted the faster year-over-year revenue change (104.7% vs -23.4%). Beyond Air, Inc. produced more free cash flow last quarter ($-4.3M vs $-7.0M). Over the past eight quarters, Insight Molecular Diagnostics Inc.'s revenue compounded faster (154.4% CAGR vs 116.1%).

Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

Delta Air Lines, Inc. is a major airline in the United States headquartered in Atlanta, Georgia, operating nine hubs, with Hartsfield–Jackson Atlanta International Airport being its largest in terms of total passengers and number of departures. With its regional subsidiaries and contractors operating under the brand name Delta Connection, Delta has over 5,400 flights daily and serves 325 destinations in 52 countries on six continents.

IMDX vs XAIR — Head-to-Head

Bigger by revenue
XAIR
XAIR
1.9× larger
XAIR
$2.2M
$1.1M
IMDX
Growing faster (revenue YoY)
XAIR
XAIR
+128.0% gap
XAIR
104.7%
-23.4%
IMDX
Higher net margin
XAIR
XAIR
1681.0% more per $
XAIR
-334.4%
-2015.4%
IMDX
More free cash flow
XAIR
XAIR
$2.8M more FCF
XAIR
$-4.3M
$-7.0M
IMDX
Faster 2-yr revenue CAGR
IMDX
IMDX
Annualised
IMDX
154.4%
116.1%
XAIR

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
IMDX
IMDX
XAIR
XAIR
Revenue
$1.1M
$2.2M
Net Profit
$-23.0M
$-7.3M
Gross Margin
42.5%
13.7%
Operating Margin
-2057.5%
-300.6%
Net Margin
-2015.4%
-334.4%
Revenue YoY
-23.4%
104.7%
Net Profit YoY
31.5%
43.7%
EPS (diluted)
$-0.75
$-0.85

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMDX
IMDX
XAIR
XAIR
Q4 25
$1.1M
$2.2M
Q3 25
$260.0K
$1.8M
Q2 25
$518.0K
$1.8M
Q1 25
$2.1M
$1.2M
Q4 24
$1.5M
$1.1M
Q3 24
$115.0K
$798.0K
Q2 24
$104.0K
$683.0K
Q1 24
$176.0K
$470.0K
Net Profit
IMDX
IMDX
XAIR
XAIR
Q4 25
$-23.0M
$-7.3M
Q3 25
$-10.9M
$-7.9M
Q2 25
$-9.7M
$-7.7M
Q1 25
$-6.7M
$-8.0M
Q4 24
$-33.5M
$-13.0M
Q3 24
$-13.5M
$-13.4M
Q2 24
$-4.5M
$-12.2M
Q1 24
$-9.1M
$-13.7M
Gross Margin
IMDX
IMDX
XAIR
XAIR
Q4 25
42.5%
13.7%
Q3 25
53.5%
-16.4%
Q2 25
67.6%
8.9%
Q1 25
62.0%
-2.8%
Q4 24
40.0%
-20.1%
Q3 24
43.5%
-135.8%
Q2 24
48.1%
-48.6%
Q1 24
25.6%
-109.4%
Operating Margin
IMDX
IMDX
XAIR
XAIR
Q4 25
-2057.5%
-300.6%
Q3 25
-4249.2%
-421.4%
Q2 25
-1900.0%
-432.8%
Q1 25
-318.0%
-622.6%
Q4 24
-2262.9%
-1021.6%
Q3 24
-11752.2%
-1608.1%
Q2 24
-4453.8%
-1988.3%
Q1 24
-5265.3%
-2687.9%
Net Margin
IMDX
IMDX
XAIR
XAIR
Q4 25
-2015.4%
-334.4%
Q3 25
-4174.6%
-436.7%
Q2 25
-1880.7%
-437.0%
Q1 25
-312.0%
-697.4%
Q4 24
-2255.1%
-1215.7%
Q3 24
-11733.0%
-1673.9%
Q2 24
-4355.8%
-1786.4%
Q1 24
-5186.9%
-2916.4%
EPS (diluted)
IMDX
IMDX
XAIR
XAIR
Q4 25
$-0.75
$-0.85
Q3 25
$-0.34
$-1.25
Q2 25
$-0.30
$-1.53
Q1 25
$-0.26
$13.26
Q4 24
$-2.19
$-2.96
Q3 24
$-0.98
$-5.67
Q2 24
$-0.36
$-5.32
Q1 24
$-1.13
$-0.36

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMDX
IMDX
XAIR
XAIR
Cash + ST InvestmentsLiquidity on hand
$11.6M
$11.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$-31.5M
$8.1M
Total Assets
$25.8M
$36.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMDX
IMDX
XAIR
XAIR
Q4 25
$11.6M
$11.7M
Q3 25
$18.7M
$10.7M
Q2 25
$24.3M
$6.5M
Q1 25
$31.0M
$6.9M
Q4 24
$8.6M
$10.9M
Q3 24
$3.4M
$28.4M
Q2 24
$9.3M
$21.4M
Q1 24
$5.6M
$34.5M
Total Debt
IMDX
IMDX
XAIR
XAIR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$11.8M
Q3 24
$12.5M
Q2 24
$17.5M
Q1 24
$17.5M
Stockholders' Equity
IMDX
IMDX
XAIR
XAIR
Q4 25
$-31.5M
$8.1M
Q3 25
$-9.2M
$12.7M
Q2 25
$1.1M
$9.9M
Q1 25
$10.2M
$13.6M
Q4 24
$-12.3M
$17.6M
Q3 24
$9.7M
$28.1M
Q2 24
$22.7M
$16.1M
Q1 24
$11.6M
$25.0M
Total Assets
IMDX
IMDX
XAIR
XAIR
Q4 25
$25.8M
$36.8M
Q3 25
$43.9M
$31.0M
Q2 25
$50.5M
$28.1M
Q1 25
$60.4M
$30.1M
Q4 24
$35.1M
$34.1M
Q3 24
$70.2M
$53.0M
Q2 24
$74.7M
$46.5M
Q1 24
$71.0M
$57.0M
Debt / Equity
IMDX
IMDX
XAIR
XAIR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.67×
Q3 24
0.44×
Q2 24
1.08×
Q1 24
0.70×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMDX
IMDX
XAIR
XAIR
Operating Cash FlowLast quarter
$-5.5M
$-4.2M
Free Cash FlowOCF − Capex
$-7.0M
$-4.3M
FCF MarginFCF / Revenue
-616.7%
-193.8%
Capex IntensityCapex / Revenue
129.9%
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-25.4M
$-22.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMDX
IMDX
XAIR
XAIR
Q4 25
$-5.5M
$-4.2M
Q3 25
$-4.5M
$-4.5M
Q2 25
$-6.3M
$-4.5M
Q1 25
$-5.9M
$-7.0M
Q4 24
$-5.4M
$-7.7M
Q3 24
$-5.5M
$-13.3M
Q2 24
$-6.0M
$-10.2M
Q1 24
$-3.8M
$-10.7M
Free Cash Flow
IMDX
IMDX
XAIR
XAIR
Q4 25
$-7.0M
$-4.3M
Q3 25
$-5.6M
$-4.7M
Q2 25
$-6.6M
$-4.7M
Q1 25
$-6.2M
$-8.5M
Q4 24
$-5.6M
$-8.3M
Q3 24
$-5.6M
$-14.5M
Q2 24
$-6.2M
$-12.9M
Q1 24
$-3.9M
$-12.7M
FCF Margin
IMDX
IMDX
XAIR
XAIR
Q4 25
-616.7%
-193.8%
Q3 25
-2135.4%
-258.5%
Q2 25
-1279.5%
-268.4%
Q1 25
-288.4%
-733.9%
Q4 24
-374.5%
-771.5%
Q3 24
-4884.3%
-1819.9%
Q2 24
-5931.7%
-1881.8%
Q1 24
-2189.8%
-2692.8%
Capex Intensity
IMDX
IMDX
XAIR
XAIR
Q4 25
129.9%
1.5%
Q3 25
403.8%
13.5%
Q2 25
67.4%
11.3%
Q1 25
14.4%
130.0%
Q4 24
14.4%
50.1%
Q3 24
75.7%
147.2%
Q2 24
183.7%
391.4%
Q1 24
13.6%
410.9%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons